Approved, Study Drugs to Be Screened For New Diseases Under NCATS, Lilly Pact

A public-private partnership announced March 13 will screen about 3,800 approved and investigational drugs for new diseases, and make the results publicly available in an effort to better predict treatment outcomes, improve drug development, and lead to more specific and effective approaches.

The collaboration is between the National Center for Advancing Translational Sciences, part of the National Institutes of Health, and drug company Eli Lilly and Co. It will screen the approved and investigational medicines in the NCATS Pharmaceutical Collection, a comprehensive publicly available database, using Eli Lilly’s Phenotypic Drug Discovery (PD2) panel.

The PD2 panel features assays designed to ...